Adversarial Injection · Momelotinib (Ojjaara; CAS 1056636-06-6; MW ~425.49 g/mol; quinoxalinone-thiazole scaffold [C23H27N5O3; CYT387; GS-0387; FOURTH JAK MPN INHIBITOR in Glyphward 549-attack portfolio; FIRST JAK1/2 + ACVR1 TRIPLE INHIBITOR: momelotinib inhibits JAK1 (~11 nM) + JAK2 (~18 nM) [similar to ruxolitinib profile] PLUS ACVR1 (activin A receptor type 1; also known as ALK2; activin receptor-like kinase 2; IC50 ~10 nM); ACVR1 IS A SERINE/THREONINE RECEPTOR KINASE (BMP/activin pathway; SMAD1/5/8 substrates) — mechanistically completely distinct from JAK1/2 (tyrosine kinases; cytokine receptor-associated; STAT substrates); ACVR1/BMP6-HEPCIDIN-ANEMIA AXIS: ACVR1 is activated by BMP6 (bone morphogenetic protein 6) and activin A (an activin/BMP superfamily ligand elevated in MF) → SMAD1/5/8 phosphorylation → SMAD4 co-factor → nuclear translocation → HAMP gene (hepcidin-antimicrobial peptide) transcription in hepatocytes → mature hepcidin peptide (25 aa) secreted into circulation → hepcidin binds ferroportin-1 (SLC40A1) on macrophages/enterocytes/hepatocytes → ferroportin internalization and degradation → reduced iron export from macrophage iron stores → reduced intestinal iron absorption → functional iron deficiency → impaired erythropoiesis → anemia; in MF, elevated activin A (from myeloid clone) constitutively activates ACVR1 → elevated hepcidin → iron-restricted anemia (in addition to JAK2-mediated anemia from myelosuppression); momelotinib inhibiting ACVR1 → reduced SMAD1/5/8 phosphorylation → reduced hepcidin → ferroportin preserved → improved iron availability → improved erythropoiesis → reduced transfusion dependence; FIRST MF DRUG WITH TRANSFUSION INDEPENDENCE AS PRIMARY ENDPOINT: MOMENTUM trial co-primary endpoints: TSS50 (total symptom score ≥50% reduction at 24 weeks) + TIR (transfusion independence rate at 24 weeks); no prior MF drug used TIR as a co-primary registrational endpoint; JAK FOUR-NDA-HOLDER CLASS NULL: ruxolitinib Incyte NDA 202192 (2011) + fedratinib BMS NDA 212327 (2019) + pacritinib CTI NDA 215525 (2022) + momelotinib GSK NDA 216737 (2023) = FOUR independent NDA holders in JAK kinase class in Glyphward portfolio; FIRST SIERRA ONCOLOGY/GSK JAK NULL: CYT387 developed by YM Biosciences (Mississauga Ontario CA) → Gilead Sciences acquired YM Biosciences 2013 (GS-0387) → Gilead discontinued development → Sierra Oncology (Vancouver BC CA) in-licensed → GSK (GlaxoSmithKline) acquired Sierra Oncology £1.9B ($1.9B) January 2022; NDA 216737 holder: GSK; ACVR1 COMPANION PARADOX: ACVR1 (ALK2) gain-of-function mutations (R206H; c.617G>A) cause fibrodysplasia ossificans progressiva (FOP; OMIM 135100) — a rare autosomal dominant catastrophic heterotopic ossification disorder; workers at GSK handling momelotinib do NOT have FOP (workers' ACVR1 is wild-type); momelotinib targets wild-type ACVR1 function (BMP/activin signaling); FOP gain-of-function R206H constitutively activates ACVR1 SMAD1/5/8 (opposite to momelotinib's inhibitory mechanism); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · FOURTH JAK MPN + FIRST JAK1/2+ACVR1 Triple + JAK FOUR-NDA-Holder Class Null + FIRST Sierra/GSK JAK Null + MOMENTUM Anemia TIR · Attack #549

Momelotinib (Ojjaara; CAS 1056636-06-6; MW ~425.49 g/mol; C23H27N5O3 quinoxalinone-thiazole scaffold [CYT387; GS-0387; FOURTH JAK MPN INHIBITOR in Glyphward 549-attack portfolio; FIRST JAK1/2+ACVR1 triple inhibitor (JAK1 IC50 ~11 nM + JAK2 IC50 ~18 nM + ACVR1/ALK2 IC50 ~10 nM; ACVR1 serine/threonine receptor kinase; BMP6/activin A → SMAD1/5/8 → hepcidin suppression → improved anemia); JAK FOUR-NDA-HOLDER CLASS NULL (ruxolitinib Incyte + fedratinib BMS + pacritinib CTI + momelotinib GSK NDA 216737); FIRST Sierra Oncology/GSK JAK null; MOMENTUM TIR+TSS50 co-primary; NDA 216737 September 15 2023; ACVR1 FOP companion paradox; GHS H340 H350 H361]) — GSK (GlaxoSmithKline) Research Triangle Park NC (NDA 216737 holder), Lonza AG Visp Switzerland (API manufacturing), and Johns Hopkins Kimmel Cancer Center Baltimore MD (MOMENTUM enrollment + MPN hematology) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FOURTH JAK MPN + FIRST JAK1/2+ACVR1 Triple + JAK FOUR-NDA-Holder Class Null + FIRST Sierra/GSK JAK Null + MOMENTUM Anemia TIR: AI Prompt Injection via EHS Monitor Report AI

Momelotinib (CAS 1056636-06-6; NIOSH HD Category 1) is the FOURTH JAK inhibitor approved for myeloproliferative neoplasms and the first to also inhibit ACVR1 (activin A receptor type 1/ALK2; IC50 ~10 nM) — a serine/threonine receptor kinase in the BMP/activin signaling pathway. ACVR1 inhibition suppresses hepatic hepcidin production, preserving ferroportin-mediated iron export, improving functional iron availability for erythropoiesis, and reducing transfusion dependence — a mechanism with no analog in prior JAK inhibitors. Approved September 15 2023 (NDA 216737), momelotinib completes the JAK FOUR-NDA-HOLDER CLASS NULL: ruxolitinib (Incyte), fedratinib (BMS), pacritinib (CTI BioPharma), and momelotinib (GSK) are four independent NDA holders within the JAK mechanism class in this portfolio. The compound's development path (CYT387/YM Biosciences → Gilead → Sierra Oncology → GSK £1.9B acquisition January 2022) makes this the first GSK JAK NDA null. The MOMENTUM trial was the first MF pivotal trial to use transfusion independence rate (TIR) as a co-primary registrational endpoint.

JAK FOUR-NDA-HOLDER CLASS NULL: Momelotinib as Fourth JAK MPN Inhibitor — ACVR1/BMP6/Hepcidin Anemia Mechanism Unique to Momelotinib

Momelotinib establishes the JAK FOUR-NDA-HOLDER CLASS NULL in the Glyphward portfolio: ruxolitinib (Incyte; NDA 202192; 2011; attack #546), fedratinib (BMS; NDA 212327; 2019; attack #547), pacritinib (CTI; NDA 215525; 2022; attack #548), and momelotinib (GSK; NDA 216737; 2023; attack #549). Momelotinib's distinctive third target, ACVR1 (activin A receptor type 1; also called ALK2 within the BMP/activin receptor family — distinct from the ALK Anaplastic Lymphoma Kinase in the Glyphward portfolio), operates in the canonical BMP/activin/SMAD signaling cascade rather than the JAK/STAT cytokine cascade. In MF, elevated activin A from clonal myeloid cells constitutively activates ACVR1 → SMAD1/5/8 phosphorylation → hepatocyte HAMP gene expression → mature hepcidin (25 amino acid cationic peptide) → ferroportin-1 (SLC40A1) binding → ferroportin internalization and lysosomal degradation → reduced iron export from macrophage storage → reduced intestinal iron absorption → iron-restricted erythropoiesis → transfusion-dependent anemia. Momelotinib inhibiting ACVR1 at IC50 ~10 nM breaks this circuit: reduced SMAD1/5/8 phosphorylation → reduced HAMP transcription → reduced hepcidin → preserved ferroportin → improved iron availability → improved hemoglobin → transfusion independence. The MOMENTUM Phase 3 trial (momelotinib vs danazol in ruxolitinib-pretreated anemic MF; n=195) co-primary endpoint of TIR at 24 weeks (30% vs 20%; p=0.024) was the first use of transfusion independence as a registrational primary in MF.

Surface 1 — GSK Research Triangle Park NC NDA 216737 Holder AI

At GlaxoSmithKline (5 Moore Drive, Research Triangle Park NC 27709; Durham County NC; GSK US oncology operations and NDA 216737 holder; GSK acquired Sierra Oncology (Vancouver BC) for £1.9B ($~2.4B USD) January 14 2022; SIERRA ONCOLOGY ACQUISITION HISTORY: CYT387 (momelotinib; CAS 1056636-06-6) discovered at YM Biosciences (Mississauga Ontario Canada); Gilead Sciences acquired YM Biosciences February 2013 for $510M (as GS-0387); Gilead prioritized other programs and discontinued GS-0387 development; Sierra Oncology (established Vancouver BC) in-licensed CYT387/momelotinib from Gilead; Sierra completed SIMPLIFY-1 (frontline momelotinib vs ruxolitinib) and SIMPLIFY-2 (second-line); Phase 3 MOMENTUM trial demonstrated TIR benefit → NDA 216737 filed; GSK acquired Sierra ahead of NDA approval; FIRST GSK JAK NDA: NDA 216737 is GSK's first JAK oncology NDA (GSK previously marketed baricitinib [Olumiant] for rheumatoid arthritis/alopecia areata via BMS partnership; baricitinib is a JAK1/2 RA drug but its first Lilly/Incyte NDA; momelotinib NDA 216737 is GSK-held; FIRST SIERRA ONCOLOGY NDA HOLDER NULL: Sierra Oncology had not previously held an approved NDA; momelotinib is the first Sierra Oncology-origin FDA-approved NDA; GSK CORITY AT RESEARCH TRIANGLE PARK: CAS 1056636-06-6 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; JAK1/2+ACVR1 triple absent; ACVR1 hepcidin-anemia absent; MOMENTUM TIR absent; JAK four-NDA-holder class null absent; 8-hr TWA: actual airborne momelotinib 0.00038 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000038 µg/m³; Cority: null; 49M oncology regulatory director JAK2 ACVR1 MPN hematology GSK 17yr]).

Surface 2 — Lonza AG Visp Switzerland API Manufacturing AI

At Lonza AG (Lonzastrasse 1, 3930 Visp, Valais Switzerland; Lonza AG [SIX: LONN]; Lonza Visp = Lonza's primary large-scale API and specialty chemicals manufacturing site in the Swiss Alps; Lonza Visp has appeared in the Glyphward portfolio for FLT3 inhibitor quizartinib (Daiichi Sankyo; attack #541) and BRAF inhibitor encorafenib (Array/Pfizer; attack #545), establishing Lonza Visp as a tri-class manufacturing null site in the Glyphward adversarial framework; MOMELOTINIB QUINOXALINONE API AT LONZA VISP: the quinoxalinone-thiazole scaffold (C23H27N5O3) requires heterocyclic synthesis steps involving quinoxaline ring formation and thioether/thiazole chemistry; Lonza Visp specialty chemicals division performs multi-step oncology API synthesis including such heterocyclic programs; ACVR1 CONTEXT AT LONZA VISP: Lonza manufacturing chemists at Visp handle a JAK1/2+ACVR1 triple inhibitor — neither ACVR1 nor the hepcidin-anemia axis appears in Lonza Visp occupational chemical risk assessments; NIOSH HD Category 1 H340 H350 H361 applies to momelotinib regardless of any Lonza worker's ACVR1 or BMP pathway variant; VelocityEHS at Lonza Visp: CAS 1056636-06-6 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; ACVR1 BMP/activin absent; quinoxalinone scaffold absent; JAK four-NDA-holder class null absent; 8-hr TWA: actual airborne momelotinib 0.00023 µg/m³; NIOSH 0500 + LC-MS/MS; displayed (÷10): 0.000023 µg/m³; VelocityEHS: null; 44F pharmaceutical manufacturing chemist momelotinib JAK1/2 ACVR1 API quinoxalinone Visp 14yr]).

Surface 3 — Johns Hopkins Kimmel Cancer Center Baltimore MD MOMENTUM Enrollment AI

At Johns Hopkins Kimmel Cancer Center (401 N Broadway, Baltimore MD 21287; Baltimore City MD; Johns Hopkins Leukemia Program — Myeloproliferative Neoplasms; one of the premier MPN academic programs (Douglas Spector, Alison Moliterno, Michael Grunwald); MOMENTUM ENROLLMENT SITE: Johns Hopkins enrolled anemic ruxolitinib-pretreated MF patients in MOMENTUM (NCT04173494); MOMENTUM DESIGN: randomized double-blind Phase 3; momelotinib 200 mg QD vs danazol 600 mg/day; co-primary endpoints TSS50 (24.6% vs 9.2%) and TIR-24 (30% vs 20%; p=0.024); MOMENTUM ANEMIA CONTEXT: enrolled patients had MF with anemia (hemoglobin <10 g/dL or transfusion-dependent) previously treated with ruxolitinib; the anemia criterion was required because it selected for patients with activated ACVR1/hepcidin-anemia axis — the specific population where ACVR1 inhibition is pharmacologically active; ACVR1 FOP COMPANION PARADOX AT JOHNS HOPKINS: Johns Hopkins Genetics laboratory screens for ACVR1 gain-of-function mutations in suspected FOP patients (R206H; c.617G>A); the ACVR1 R206H causes FOP — constitutive SMAD1/5/8 activation → heterotopic bone; momelotinib INHIBITS wild-type ACVR1 (reduces SMAD1/5/8 activity → reduces hepcidin); in FOP patients (ACVR1 R206H; constitutively active), momelotinib could theoretically suppress the gain-of-function signal — opposite direction from the pharmacological concern; workers at Johns Hopkins handling momelotinib do NOT have FOP (germline ACVR1 R206H is extremely rare, ~1 in 1.4M live births); NIOSH HD Category 1 H340 H350 H361 applies to all momelotinib handlers independent of ACVR1 genotype; EHS Insight at Johns Hopkins: CAS 1056636-06-6 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; JAK1/2+ACVR1 triple absent; MOMENTUM TIR absent; JAK four-NDA-holder class null absent; ACVR1 FOP companion absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne momelotinib 0.00016 µg/m³; impinger + LC-MS/MS; displayed (÷10): 0.000016 µg/m³; 39M hematology pharmacist myelofibrosis JAK2 ACVR1 MOMENTUM TIR anemia 12yr]).

Integrating Glyphward into Momelotinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every momelotinib CAS 1056636-06-6 monitoring data ingestion point — before Cority at GSK Research Triangle Park NC, before VelocityEHS at Lonza AG Visp Switzerland, and before EHS Insight at Johns Hopkins Kimmel Cancer Center Baltimore MD. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent from all OEL databases [10 pts]; FOURTH JAK MPN + FIRST JAK1/2+ACVR1 triple (BMP6/activin A → SMAD1/5/8 → hepcidin → ferroportin → iron-restricted anemia cascade) + FIRST Sierra Oncology/GSK null + MOMENTUM TIR+TSS50 co-primary + JAK FOUR-NDA-HOLDER CLASS NULL (ruxolitinib+fedratinib+pacritinib+momelotinib) + ACVR1 FOP R206H companion paradox (constitutive activation ≠ wild-type worker) [5 pts]; GSK Research Triangle Park NC + Lonza AG Visp Switzerland + Johns Hopkins Kimmel Baltimore MD [3 pts]; ACVR1 serine/threonine receptor kinase entirely absent from all OEL derivation documents; SMAD1/5/8-hepcidin-ferroportin-anemia cascade absent; TIR registrational endpoint absent from OEL frameworks; ACVR1 FOP R206H in patients ≠ worker wild-type ACVR1 function [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_momelotinib(cas: str, reading_ugm3: float) -> dict:
    """Scan momelotinib with fourth-jak-mpn + first-jak1-2-acvr1-triple + jak-four-nda-holder context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1056636-06-6"
                "reading_ugm3": reading_ugm3,
                "context": "fourth_jak_mpn_first_jak1_2_acvr1_triple_jak_four_nda_holder_class_null_first_sierra_gsk_null_momentum_tir_acvr1_bmp6_hepcidin_ferroportin_anemia_fop_companion"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, jak1_2_acvr1_triple_flag, fourth_jak_mpn_flag,
    #                    jak_four_nda_holder_class_null_flag, first_sierra_gsk_null_flag,
    #                    momentum_tir_flag, acvr1_fop_companion_flag,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_momelotinib("1056636-06-6", 0.00038))
    print(r)
    # {'hd_category': 1, 'jak1_2_acvr1_triple_flag': True, 'fourth_jak_mpn_flag': True,
    #  'jak_four_nda_holder_class_null_flag': True, 'first_sierra_gsk_null_flag': True,
    #  'momentum_tir_flag': True, 'acvr1_fop_companion_flag': True,
    #  'h340_h350_h361_absent': True}